EUVIMEDEUVIMED entdecken
Crossref

Final 5‐Year Results of Abluminal Groove‐Filled Biodegradable‐Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent in Patients With Diabetes: Results of the TARGET AC Trial

Yasin Hussain iD, William Wijns iD, Andreas Baumbach iD, Niels van Royen iD, Henning Kelbæk iD, Richard Anderson, Volker Schächinger iD, Ernest Spitzer iD, Wietze Lindeboom, Rishi Tripathi, Laya Ohadi, Dominic P Francese iD und 3 weitere

Catheterization and Cardiovascular Interventions · 01.11.2026

DOI: 10.1002/ccd.70966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 01.11.2026. Verfasst von Yasin Hussain und 14 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Die Arbeit nennt 34 Literaturangaben. Gefördert von: MicroPort.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with diabetes mellitus (DM) undergoing PCI are at high risk of restenosis and late stent thrombosis. The Firehawk stent (abluminal biodegradable‐polymer sirolimus‐eluting stent [SES]) is designed to minimize inflammation and enhance vascular healing, which may improve outcomes in patients with DM.

Aims

In this subgroup analysis of the TARGET All Comers trial, we compared 5‐year outcomes of patients based on diabetes status treated with the Firehawk SES versus XIENCE everolimus‐eluting stent (EES).

Methods

TARGET All Comers randomized patients 1:1 to Firehawk or XIENCE. In this analysis, we compare non‐stratified outcomes in DM versus non‐DM patients overall and based on stent type. The primary end point was target lesion failure (TLF) at 5 years, a composite of cardiac death, target vessel myocardial infarction (TVMI), or ischemia‐driven target lesion revascularization (TLR). Secondary end points included components of the primary outcome and definite/probable stent thrombosis.

Results

Of the 1651 patients enrolled, 388 (23%) had DM (197 Firehawk and 191 XIENCE) and 1263 (77%) had no DM (624 Firehawk and 639 XIENCE). Patients with DM were older, had more hypertension, hyperlipidemia, and more prior coronary interventions. Compared with non‐DM patients, TLF ( p < 0.001), cardiac death ( p < 0.001), TVMI ( p = 0.002), ischemia‐driven TLR ( p < 0.001), and definite/probable stent thrombosis ( p = 0.008) were more frequent in patients with DM. There were no differences in primary or secondary end points between Firehawk and XIENCE in patients with or without DM.

Conclusion

This subgroup analysis of the multicenter TARGET All Comers trial shows that at 5 years, the rate of TLF among patients with DM was similar with the Firehawk SES and the XIENCE EES. Our analysis demonstrates that regardless of stent type, patients with DM have higher rates of TLF.

Schlagwörter

Stichwörter der Autor:innen

coronary artery diseasediabetes mellitusdrug‐eluting stentspercutaneous coronary intervention

Autor:innen und Institutionen

  • Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • The Lambe Institute for Translational Medicine and Curam, University of Galway, Galway, Ireland.
  • Barts Heart Centre, Queen Mary University of London, London, UK.
  • Department of Cardiology, VU University Medical Centre, Amsterdam, the Netherlands.
  • Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff, UK.

ORCID-Profile: Yasin Hussain, William Wijns, Andreas Baumbach, Niels van Royen, Henning Kelbæk, Volker Schächinger, Ernest Spitzer, Dominic P Francese, Daniela Tirziu, Alexandra J Lansky

Förderung

  • MicroPort

Zitieren

APA

Hussain, Y., Wijns, W., Baumbach, A., van Royen, N., Kelbæk, H., Anderson, R., Schächinger, V., Spitzer, E., Lindeboom, W., Tripathi, R., Ohadi, L., Francese, D. P., Tirziu, D., Lansky, A. J., & TARGET All Comers Investigators (2026). Final 5‐Year Results of Abluminal Groove‐Filled Biodegradable‐Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent in Patients With Diabetes: Results of the TARGET AC Trial. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70966

Vancouver

Hussain Y, Wijns W, Baumbach A, van Royen N, Kelbæk H, Anderson R, et al. Final 5‐Year Results of Abluminal Groove‐Filled Biodegradable‐Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent in Patients With Diabetes: Results of the TARGET AC Trial. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70966

BibTeX
@article{Hussain2026,
  author = {Hussain, Yasin and Wijns, William and Baumbach, Andreas and van Royen, Niels and Kelbæk, Henning and Anderson, Richard and Schächinger, Volker and Spitzer, Ernest and Lindeboom, Wietze and Tripathi, Rishi and Ohadi, Laya and Francese, Dominic P and Tirziu, Daniela and Lansky, Alexandra J and TARGET All Comers Investigators, TARGET All Comers Investigators},
  title = {Final 5‐Year Results of Abluminal Groove‐Filled Biodegradable‐Polymer Sirolimus‐Eluting Stent Versus Durable‐Polymer Everolimus‐Eluting Stent in Patients With Diabetes: Results of the TARGET AC Trial},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70966}
}
Kostenlos starten →